Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
all-trans-retinoic acid + IFN-alpha2a
- Development stage
- Unknown
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
This drug is a combination therapy consisting of all-trans-retinoic acid (ATRA) and interferon alpha-2a (IFN-alpha2a). ATRA is a derivative of vitamin A that induces differentiation and inhibits proliferation in certain cancer cells. IFN-alpha2a is a recombinant cytokine with antiproliferative, immunostimulatory, antiviral, and differentiation-potentiating effects. The rationale for combining these agents lies in their complementary mechanisms—ATRA promotes cellular differentiation while IFN-alpha2a enhances immune response and may potentiate the effects of retinoids. This combination has been investigated primarily in pediatric oncology for refractory neuroblastoma and Wilms tumor but did not demonstrate significant clinical activity in phase 1/2 trials[1][2][5]. The regimen was generally well tolerated; headache was the most common toxicity.
- Brand names
- VesanoidRoferon-A
- Other names
- ATRA + IFN-alpha2aall-trans retinoic acid and interferon alpha-2aATRA/IFN-alpha2a
02
Targets
RARA (Retinoic acid receptor alpha)IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR1 (Interferon alpha/beta receptor 1)
Beyond the preview
Go deeper on all-trans-retinoic acid + IFN-alpha2a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on all-trans-retinoic acid + IFN-alpha2a.